Cargando…

Survival, prognostic factors, hospitalization time and clinical performance status after first cerebral relapse or progression in 54 patients with primary CNS lymphoma not eligible for high dose chemotherapy: a retrospective analysis

BACKGROUND: Treatment of relapsed or refractory primary CNS lymphoma (r/r PCNSL) is difficult, particularly in patients not eligible for high dose chemotherapy with autologous stem cell transplantation (HDC-ASCT). No standard treatment has been defined for these patients yet. METHODS: We retrospecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seidel, Sabine, Kowalski, Thomas, Nilius-Eliliwi, Verena, Schroers, Roland, Schlegel, Uwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948364/ https://www.ncbi.nlm.nih.gov/pubmed/36814351 http://dx.doi.org/10.1186/s42466-023-00234-y

Ejemplares similares

High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Primary CNS Lymphoma: A Retrospective Monocentric Analysis of Long-Term Outcome, Prognostic Factors, and Toxicity
por: Seidel, Sabine, et al.
Publicado: (2022)

High-dose chemotherapy and autologous stem cell transplantation in primary lymphomatoid granulomatosis of the central nervous system
por: Nilius-Eliliwi, Verena, et al.
Publicado: (2022)

Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
por: Aydilek, Enver, et al.
Publicado: (2023)

HDMTX-based polychemotherapy including intraventricular therapy in elderly patients with primary CNS lymphoma: a single center series
por: Seidel, Sabine, et al.
Publicado: (2020)

Patients with Primary Central Nervous System Lymphoma Not Eligible for Clinical Trials: Prognostic Factors, Treatment and Outcome
por: Seidel, Sabine, et al.
Publicado: (2021)

The value of bone marrow biopsy for staging of patients with primary CNS lymphoma
por: Margold, Michelle, et al.
Publicado: (2021)

HDMTX-based induction therapy followed by consolidation with conventional systemic chemotherapy and intraventricular therapy (modified Bonn protocol) in primary CNS lymphoma: a monocentric retrospective analysis
por: Seidel, Sabine, et al.
Publicado: (2019)

Quantification of cell-free DNAfor the analysis of CD19-CAR-T cells during lymphoma treatment
por: Mika, Thomas, et al.
Publicado: (2021)

Treatment of leptomeningeal disease in blastic plasmacytoid dendritic cell neoplasm following tagraxofusp-erzs induction
por: Vangala, Deepak B., et al.
Publicado: (2022)

Optical Genome Mapping in MDS and AML as tool for structural variant profiling—comment and data update on Yang et al.: “High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance”
por: Vangala, Deepak B., et al.
Publicado: (2022)

Optical Genome Mapping for Cytogenetic Diagnostics in AML
por: Nilius-Eliliwi, Verena, et al.
Publicado: (2023)

Successful Chimeric Antigen Receptor (CAR) T-Cell Treatment in Aggressive Lymphoma Despite Coronavirus Disease 2019 (CoVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication - Case Report
por: Nilius-Eliliwi, Verena, et al.
Publicado: (2021)

Optical Genome Mapping Reveals and Characterizes Recurrent Aberrations and New Fusion Genes in Adult ALL
por: Vieler, Lisa-Marie, et al.
Publicado: (2023)

Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway
por: Althaus, Jonas, et al.
Publicado: (2023)

Novel NUP98::ASH1L Gene Fusion in Acute Myeloid Leukemia Detected by Optical Genome Mapping
por: Tembrink, Marco, et al.
Publicado: (2023)

ML-02 Chemotherapy for patients with relapsed or refractory primary CNS lymphoma
por: Nagane, Motoo, et al.
Publicado: (2020)

Treatment Strategies and Prognostic Factors in Secondary Central Nervous System Lymphoma: A Multicenter Study of 124 Patients
por: Treiber, Hannes, et al.
Publicado: (2023)

Relapse pattern and prognosis of primary CNS lymphoma
por: Dahiya, Saurabh, et al.
Publicado: (2012)

ML-8 HIGH-DOSE CHEMOTHERAPY SUPPORTED BY AN AUTOLOGOUS STEM CELL TRANSPLANT IN RELAPSED PRIMARY CNS LYMPHOMA
por: Mishima, Kazuhiko, et al.
Publicado: (2022)

ML-18 High-dose chemotherapy supported by autologous stem cell transplant in relapsed and refractory primary CNS lymphoma
por: Nagane, Motoo, et al.
Publicado: (2021)

Salvage chemotherapy with R-BAD (rituximab, bendamustine, cytarabine, and dexamethasone) for the treatment of relapsed primary CNS lymphoma
por: Cho, Min-Seok, et al.
Publicado: (2016)

Relapse pattern and prognostic factors for patients with primary CNS lymphoma
por: Suh, Cheolwon, et al.
Publicado: (2012)

Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma
por: Seidel, Sabine, et al.
Publicado: (2020)

A Successful Treatment of Relapsed Primary CNS Lymphoma Patient with Intraventricular Rituximab Followed by High-Dose Chemotherapy with Autologous Stem Cell Rescue
por: Hong, Sung Jin, et al.
Publicado: (2009)

Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice
por: Ambady, Prakash, et al.
Publicado: (2021)

Cranial Radiation Therapy as Salvage in the Treatment of Relapsed Primary CNS Lymphoma
por: Volpini, Matthew E., et al.
Publicado: (2022)

Real-world experiences of CNS-directed chemotherapy followed by autologous stem cell transplantation for secondary CNS involvement in relapsed or refractory diffuse large B-cell lymphoma
por: Jeong, Sun Young, et al.
Publicado: (2023)

High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma
por: Ong, Shin Yeu, et al.
Publicado: (2021)

Broad genomic workup including optical genome mapping uncovers a DDX3X: MLLT10 gene fusion in acute myeloid leukemia
por: Nilius-Eliliwi, Verena, et al.
Publicado: (2022)

NQPC-5 Does high-dose methotrexate-based chemotherapy for relapsed primary CNS lymphoma increase a risk of leukoencephalopathy with prior whole brain radiotherapy?
por: Kobayashi, Keiichi, et al.
Publicado: (2021)

Is There an Indication for First Line Radiotherapy in Primary CNS Lymphoma?
por: Seidel, Clemens, et al.
Publicado: (2021)

CNS Genes Implicated in Relapse
por: Kuntz-Melcavage, Kara L, et al.
Publicado: (2008)

Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
por: Bobillo, Sabela, et al.
Publicado: (2021)

PB2334: CENTRAL NERVOUS SYSTEM (CNS) RELAPSE IN DIFFUSE LARGE B-CELL LYMPHOMA: CNS-SAMATYA RISK MODEL
por: Yokus, Osman, et al.
Publicado: (2023)

SS-4 High dose chemotherapy with autologous hematopoietic stem cell transplantation for CNS lymphoma
por: Kondo, Eisei
Publicado: (2020)

Clinical outcomes in transplant‐eligible patients with relapsed or refractory diffuse large B‐cell lymphoma after second‐line salvage chemotherapy: A retrospective study
por: Yagi, Yu, et al.
Publicado: (2023)

MicroRNAs as predictors for CNS relapse of systemic diffuse large B-cell lymphoma
por: Pillar, Nir, et al.
Publicado: (2017)

CNS relapse of diffuse large B cell Lymphoma A single centre experience
por: Nazir, Adil, et al.
Publicado: (2017)

Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab
por: Elhassadi, Ezzat, et al.
Publicado: (2018)

Impact of bone marrow involvement on outcome in relapsed and refractory transplant eligible diffuse large B-cell lymphoma and transformed indolent lymphoma
por: Terziev, Denis, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e1r3uo12o3flfqncce22jja1a3